lilly oral glp-1 is now pharma's top revenue company. It just got FDA approval for an GLP-1, but Wall Street isn't celebrating Eli Lilly's orforglipron: a new
Description
doi: 10.1056/NEJMoa1611925
Diabetologia 56 , 965972 (2013)

This would finally align CHAMPVA with the standard set by the Affordable Care Act for private insurance

Maloney A, Rosenstock J, Fonseca V Clin Pharmacol Ther

Nevertheless, the use of GLP-medications among U.S

Patients should work closely with their doctors to determine the best approach for their individual needs
